Literature DB >> 27111872

Disease Activity As a Major Determinant of Quality of Life and Physical Function in Patients With Early Axial Spondyloarthritis.

Cristina Fernández-Carballido1, Victoria Navarro-Compán2, Concepción Castillo-Gallego3, Maria C Castro-Villegas4, Eduardo Collantes-Estévez4, Eugenio de Miguel2.   

Abstract

OBJECTIVE: To describe health-related quality of life (HRQOL) and physical function in patients with early axial spondyloarthritis (SpA) and to assess their associations with disease activity and radiographic damage.
METHODS: This was a cross-sectional study drawing upon baseline data of axial SpA patients (Assessment of SpondyloArthritis international Society criteria) from the ESPERANZA cohort. Linear regression analyses were used to evaluate the associations between disease activity and radiographic damage (spine and sacroiliac joints) with HRQOL, physical function, and spinal mobility.
RESULTS: In total, 259 patients were included. The mean ± SD age was 32.2 ± 6.9 years, disease duration was 13.3 ± 6.8 months, Ankylosing Spondylitis Quality of Life score was 5.9 ± 4.8, Bath Ankylosing Spondylitis Functional Index score was 2.4 ± 2.3, Bath Ankylosing Spondylitis Metrology Index score was 1.4 ± 1.3, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score was 3.8 ± 2.3, C-reactive protein (CRP) level was 9.7 ± 13.2 mg/liter, and Bath Ankylosing Spondylitis Radiology Index for the spine (BASRI-s) score was 1.7 ± 1.6. HRQOL was mainly associated with disease activity on univariate analysis (β values for BASDAI 0.646, patient global visual analog scale [VAS] 0.641, night back pain VAS 0.598, physician VAS 0.560, and CRP level 0.275; P < 0.01 for all), whereas the association with radiographic damage was weaker (standardized β for BASRI-s 0.142; P < 0.05). On multivariate models, HRQOL only remained significantly associated with disease activity (standardized β for BASDAI 0.330; P < 0.01, and physician VAS 0.205 and night back pain VAS 0.210; P = 0.01). Similarly, physical function was associated with disease activity and radiographic damage on univariate analysis, but only with disease activity (BASDAI β 0.466; P < 0.01) on multivariate analysis. However, spinal mobility was associated with radiographic damage in both univariate and multivariate analyses.
CONCLUSION: Patients with axial SpA already have impaired quality of life and physical function, albeit mildly, at the beginning of their disease course. Both outcomes are mainly associated with disease activity in these patients.
© 2016, American College of Rheumatology.

Entities:  

Mesh:

Year:  2016        PMID: 27111872     DOI: 10.1002/acr.22908

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  9 in total

1.  Are extra-spinal symptoms associated with quality of life in patients with axial spondyloarthritis? A 1-year follow-up study.

Authors:  Yu Heng Kwan; Warren Fong; Ying Ying Leung; Nai Lee Lui; Chuen Seng Tan; Rahul Malhotra; Truls Østbye; Julian Thumboo
Journal:  Clin Rheumatol       Date:  2019-03-23       Impact factor: 2.980

2.  Changes of patient-reported outcomes and protein fingerprint biomarkers after exercise therapy for axial spondyloarthritis.

Authors:  Marketa Husakova; Anne Sofie Siebuhr; Karel Pavelka; Maja Spiritovic; Anne-Christine Bay-Jensen; Andrea Levitova
Journal:  Clin Rheumatol       Date:  2017-08-30       Impact factor: 2.980

3.  Evaluation of quality of life in patients with axial spondyloarthritis and its association with disease activity, functionality, mobility, and structural damage.

Authors:  Clementina López-Medina; Juan L Garrido-Castro; Juan Castro-Jiménez; Cristina González-Navas; Jerusalem Calvo-Gutiérrez; M Carmen Castro-Villegas; Rafaela Ortega-Castro; Alejandro Escudero-Contreras; Pilar Font-Ugalde; Eduardo Collantes-Estévez
Journal:  Clin Rheumatol       Date:  2018-04-24       Impact factor: 2.980

4.  Quality of life and correlation with clinical and radiographic variables in patients with ankylosing spondylitis: a retrospective case series study.

Authors:  Ji-Chen Huang; Bang-Ping Qian; Yong Qiu; Bin Wang; Yang Yu; Ze-Zhang Zhu; Jun Hu; Zhe Qu
Journal:  BMC Musculoskelet Disord       Date:  2017-08-15       Impact factor: 2.362

5.  Challenges to conquer from the gender perspective in medicine: The case of spondyloarthritis.

Authors:  Vega Jovani; Mar Blasco-Blasco; Eliseo Pascual; M Teresa Ruiz-Cantero
Journal:  PLoS One       Date:  2018-10-12       Impact factor: 3.240

6.  Similar alteration for mental and physical aspects in health-related quality of life over 5 to 8 years in 1347 patients with early arthritis and early inflammatory back pain.

Authors:  Déborah Puyraimond-Zemmour; Benjamin Granger; Anna Molto; Cécile Gaujoux-Viala; Francis Guillemin; Adeline Ruyssen-Witrand; Maxime Dougados; Bruno Fautrel; Laure Gossec
Journal:  Arthritis Res Ther       Date:  2019-02-19       Impact factor: 5.156

7.  Factors related to health-related quality of life in ankylosing spondylitis, overall and stratified by sex.

Authors:  Lucy Law; Jeanette Beckman Rehnman; Anna Deminger; Eva Klingberg; Lennart T H Jacobsson; Helena Forsblad-d'Elia
Journal:  Arthritis Res Ther       Date:  2018-12-27       Impact factor: 5.156

Review 8.  Taiwan Rheumatology Association consensus recommendations for the management of axial spondyloarthritis.

Authors:  James Cheng-Chung Wei; Chin-Hsiu Liu; Jui-Cheng Tseng; Lin-Fen Hsieh; Chun-Hsiung Chen; Hsin-Hua Chen; Hung-An Chen; Ying-Chou Chen; Chung-Tei Chou; Hsien-Tzung Liao; Yi-Chun Lin; Shue-Fen Luo; Deng-Ho Yang; Kai-Jieh Yeo; Wen-Chan Tsai
Journal:  Int J Rheum Dis       Date:  2019-11-27       Impact factor: 2.454

9.  Determinants of the patient global assessment of well-being in early axial spondyloarthritis: 5-year longitudinal data from the DESIR cohort.

Authors:  Fumio Hirano; Désirée van der Heijde; Floris A van Gaalen; Robert B M Landewé; Cécile Gaujoux-Viala; Sofia Ramiro
Journal:  Rheumatology (Oxford)       Date:  2021-01-05       Impact factor: 7.580

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.